BR112015021668A2 - agonista de receptor ß2-adrenérgico para melhorar a correspondência de cor de pele de cicatriz - Google Patents

agonista de receptor ß2-adrenérgico para melhorar a correspondência de cor de pele de cicatriz

Info

Publication number
BR112015021668A2
BR112015021668A2 BR112015021668A BR112015021668A BR112015021668A2 BR 112015021668 A2 BR112015021668 A2 BR 112015021668A2 BR 112015021668 A BR112015021668 A BR 112015021668A BR 112015021668 A BR112015021668 A BR 112015021668A BR 112015021668 A2 BR112015021668 A2 BR 112015021668A2
Authority
BR
Brazil
Prior art keywords
individual
hyperpigmentation
skin color
scar
adrenergic receptor
Prior art date
Application number
BR112015021668A
Other languages
English (en)
Other versions
BR112015021668B1 (pt
Inventor
Elaine Pullar Christine
Original Assignee
Univ Leicester
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Leicester filed Critical Univ Leicester
Publication of BR112015021668A2 publication Critical patent/BR112015021668A2/pt
Publication of BR112015021668B1 publication Critical patent/BR112015021668B1/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/40—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing nitrogen
    • A61K8/41—Amines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/49—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds
    • A61K8/4906—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with one nitrogen as the only hetero atom
    • A61K8/4926—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with one nitrogen as the only hetero atom having six membered rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/16—Emollients or protectives, e.g. against radiation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q17/00—Barrier preparations; Preparations brought into direct contact with the skin for affording protection against external influences, e.g. sunlight, X-rays or other harmful rays, corrosive materials, bacteria or insect stings
    • A61Q17/04—Topical preparations for affording protection against sunlight or other radiation; Topical sun tanning preparations
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A61Q19/02—Preparations for care of the skin for chemically bleaching or whitening the skin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
    • A61K2800/74—Biological properties of particular ingredients
    • A61K2800/78—Enzyme modulators, e.g. Enzyme agonists

Abstract

resumo da patente de invenã§ã£o para: “agonista de receptor î²2-adrenã‰rgico para melhorar a correspondãšncia de cor de pele de cicatriz”. um mã©todo para melhorar a correspondãªncia de cor de pele de cicatriz, por exemplo, reduzindo a hiperpigmentaã§ã£o de cicatriz, o mã©todo compreendendo a administraã§ã£o de uma quantidade terapeuticamente eficaz de um agente, o qual modula positivamente conformaã§ã£o de receptor î²2-adrenã©rgico, ou a atividade do receptor, ou a ativaã§ã£o dos mesmos, a um indivã­duo em necessidade dos mesmos. o indivã­duo tipicamente estã¡ em necessidade de melhorar a correspondãªncia de cor de pele de cicatriz, por exemplo reduzindo hiperpigmentaã§ã£o de cicatriz, porque o indivã­duo tem ou estã¡ em risco de hiperpigmentaã§ã£o. o indivã­duo ã© tipicamente selecionado como estando em risco de hiperpigmentaã§ã£o com base em um ou mais dos seguintes fatores: • o indivã­duo jã¡ havia desenvolvido previamente hiperpigmentaã§ã£o de uma cicatriz• o indivã­duo se bronzeia prontamente quando exposto ao sol ou radiaã§ã£o ultravioleta (uv), em vez de se queimar• o indivã­duo tem uma origem racial nã£o-caucasiana• a cor de pele do indivã­duo (por exemplo, em uma ã¡rea que nã£o ã© bronzeada) ã© tida como sendo mais escura que o tã­pico para uma pessoa caucasiana de cabelo louro. o indivã­duo pode ser selecionado como estando em risco de hiperpigmentaã§ã£o, porque sã£o, pelo menos, predominantemente chineses, negros africanos, asiã¡ticos ou sul-europeus e/ou se o seu tipo de pele pode ser avaliado segundo a escala de fitzpatrick como tipo iii, iv, v ou vi.
BR112015021668-4A 2013-03-08 2014-03-07 Agonista de receptor ss2-adrenérgico para melhorar a correspondência de cor de pele de cicatriz BR112015021668B1 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB1304234.6A GB2513297A (en) 2013-03-08 2013-03-08 Methods
GB1304234.6 2013-03-08
PCT/GB2014/050686 WO2014135896A2 (en) 2013-03-08 2014-03-07 Methods

Publications (2)

Publication Number Publication Date
BR112015021668A2 true BR112015021668A2 (pt) 2017-07-18
BR112015021668B1 BR112015021668B1 (pt) 2022-03-08

Family

ID=48189617

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112015021668-4A BR112015021668B1 (pt) 2013-03-08 2014-03-07 Agonista de receptor ss2-adrenérgico para melhorar a correspondência de cor de pele de cicatriz

Country Status (9)

Country Link
US (1) US9943471B2 (pt)
EP (1) EP2964206B1 (pt)
JP (1) JP6496670B2 (pt)
KR (1) KR20150128695A (pt)
BR (1) BR112015021668B1 (pt)
DK (1) DK2964206T3 (pt)
ES (1) ES2748609T3 (pt)
GB (1) GB2513297A (pt)
WO (1) WO2014135896A2 (pt)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104606177B (zh) * 2014-11-21 2018-02-02 苏州君宁新药开发中心有限公司 左旋(r)沙丁胺醇制剂在治疗皮肤及粘膜创伤溃疡的药物应用
CN110841208B (zh) * 2018-08-21 2023-05-02 魏琳 一种美白祛斑美容仪

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2740040B1 (fr) 1995-10-23 1997-12-05 Oreal Utilisation d'au moins un agoniste beta-adrenergique en tant qu'antagoniste de substance p
AU6233201A (en) 2000-06-05 2001-12-17 Byk Gulden Lomberg Chem Fab Compounds effective as beta-2-adrenoreceptor agonists as well as pde4-inhibitors
EA007906B1 (ru) 2002-04-19 2007-02-27 Астион Девелопмент А/С Комбинация агониста бета-2-адренорецепторов и аминосахара и их применение для лечения иммуномодуляторных расстройств
WO2006027579A2 (en) 2004-09-07 2006-03-16 Sosei R & D Ltd. The treatment of inflammatory disorders and pain
US20100215710A1 (en) * 2005-04-08 2010-08-26 The Regents Of The University Of California Beta-2 Adrenergic Receptor Agonists and Antagonists and Modulation of Wound Healing
WO2006108424A2 (en) * 2005-04-13 2006-10-19 Astion Pharma A/S Beta-2 adrenoceptor agonists for treating connective tissue diseases of the skin
EP1764081A1 (en) 2005-08-29 2007-03-21 Johnson & Johnson Consumer France SAS Sunscreen composition comprising a dibenzoylmethane, an aminohydroxybenzophenone, a triazine and a triazole as UV filters
EP2018162A2 (en) 2006-05-18 2009-01-28 Tika Läkemedel AB Methods for the delivery of a beta2 agonist to induce bronchodilation and formulations for use in the same
EP2200572A2 (en) 2007-09-18 2010-06-30 Schering-Plough Healthcare Products, Inc. Sunscreen compositions with low eye-sting and high spf
GB0724204D0 (en) * 2007-12-12 2008-01-23 Renovo Ltd Methods for inhibition of scarring
GB0805535D0 (en) * 2008-03-27 2008-04-30 Univ Leicester Scar prevention
CN103764107B (zh) 2011-06-08 2015-04-22 玫琳凯有限公司 防晒制剂

Also Published As

Publication number Publication date
ES2748609T3 (es) 2020-03-17
GB201304234D0 (en) 2013-04-24
US20160008247A1 (en) 2016-01-14
US9943471B2 (en) 2018-04-17
WO2014135896A2 (en) 2014-09-12
BR112015021668B1 (pt) 2022-03-08
DK2964206T3 (da) 2019-10-07
EP2964206B1 (en) 2019-07-17
JP2016510061A (ja) 2016-04-04
GB2513297A (en) 2014-10-29
KR20150128695A (ko) 2015-11-18
JP6496670B2 (ja) 2019-04-03
WO2014135896A3 (en) 2014-11-13
EP2964206A2 (en) 2016-01-13

Similar Documents

Publication Publication Date Title
Vachiramon et al. Melasma in men
BR112015013700A2 (pt) composição, sequência nucleotídica, anticorpo sintético, e, uso da composição
BR112015027528A2 (pt) polipeptídeo, combinação farmacêutica, métodos de tratamento de um distúrbio metabólico e de obesidade, uso de um polipeptídeo ou de uma combinação farmacêutica, molécula de ácido nucleico, vetor de expressão, e, célula hospedeira
BR112017025221A2 (pt) composições cosméticas compreendendo esclareolida
BR112014011925A2 (pt) mutações no receptor notch humano e seu uso
BR112019001142A2 (pt) vírus vaccinia recombinante e uso do mesmo
BR112018073037A2 (pt) métodos para tratar um distúrbio do ritmo sono-vigília irregular e pelo menos um distúrbio do sono do ritmo circadiano, para melhorar continuidade do sono noturno, comportamentos e dificuldades cognitivas e pelo menos uma dificuldade comportamental e/ou cognitiva, para tratar sonolência e/ou cochilos diurnos excessivos, e, para estabilizar e para melhorar um ou mais ritmos circadianos.
BR112018074981A2 (pt) tratamentos de câncer
EP2590106A3 (en) Security and safety manager implementation in a multi-core processor
BR112015030355A2 (pt) método para tratar, melhorar, inverter, proteger ou prevenir um indivíduo ou um paciente contra uma patologia, uma cardiopatia ou uma doença cardiovascular, uso, e, formulação terapêutica
BR112015021668A2 (pt) agonista de receptor ß2-adrenérgico para melhorar a correspondência de cor de pele de cicatriz
BRPI0514453A (pt) sistema aquoso de liberação de enzima
Zhou et al. Differential responses to UVB irradiation in human keratinocytes and epidermoid carcinoma cells
BR112016002580A2 (pt) composição para tratamento antienvelhecimento de pele
BR112015001299A2 (pt) sistema, estação de trabalho e método
BR112012021532A2 (pt) composição para tratamento de unhas com fungo
BR112015026588A2 (pt) uso cosmético, composição e método cosmético
BR112014019602A8 (pt) Uso do extrato de carambola como um modulador de cpt1 e composições do mesmo
BR112014032802A2 (pt) composições compreendendo fenóis substituídos e aplicação tópica das mesmas
BRPI0517216A (pt) uso cosmético de pelo menos um antagonista dos receptores periféricos das benzodizepinas e processo cosmético para combater as rugas ou as rìdulas
Xianjun et al. Impacts of blueberry extract on the memory and anti-aging role of laboratory mouse
苏舒燕 On Impact of Cultural Differences upon the English-Chinese Advertising Translation
Cheng et al. 114. Toll-like receptor 9 agonist suppresses angiogenesis by differentially regulating VEGFA and sFLT1 in preeclampsia
Díaz-Reixa et al. Nephron-sparing surgery for renal tumours on kidney transplantation
Galderisi S16-01-Primary and enduring negative symptoms in first episode and chronic patients with schizophrenia

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 07/03/2014, OBSERVADAS AS CONDICOES LEGAIS.